why choose us

First received: September 22, 2024

Clinical Trial: Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Renal Cell Cancer Metastatic

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Study of the Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue.

Brief Summary: Fatigue is a prevalent adverse event associated with systemic therapy using tyrosine kinase inhibitors (TKIs).Meldonium, a fatty acid oxidation inhibitor, modifies the carnitine pathway, a nutrient critical for fat metabolism.The World Anti-Doping Agency (WADA) classified meldonium as a banned substance due to its documented use by athletes aiming to enhance physical performance.In this study, the safety and preliminary efficacy of meldonium in treatment-related fatigue will be assessed.

Read more